Medication-Related Osteonecrosis of the Jaws: A Comparison of SICMF-SIPMO and AAOMS Guidelines

(1) Background: Medication-related osteonecrosis of the jaws (MRONJ) is an adverse drug reaction characterized by progressive bone disruption and necrosis in the mandibular and/or maxillary bones. It occurs in individuals who have received antiresorptive drugs without prior radiotherapy. Since its first reported cases in the USA in 2003, extensive literature has emerged worldwide, leading to significant advancements in understanding MRONJ's pathogenesis and management. (2) Results: This article aims to compare the current national recommendations provided by the Italian Society of Maxillofacial Surgery (SICMF)/Italian Society of Oral Pathology and Medicine (SIPMO) and the American Association of Oral and Maxillofacial Surgeons (AAOMS). (3) Conclusions: Historically, the AAOMS advocated for a more conservative approach compared to the Italian guidelines. However, in their 2022 update, the AAOMS adopted a different perspective based on reported evidence, highlighting the advantages of early surgical treatment. Despite resolving some initial controversies, differences still exist between the two sets of recommendations, particularly regarding diagnosis and staging.

Augmentation of atrophic posterior maxilla by short implants and osteotome technique

INTRODUCTION. Edentulous ridge in the posterior maxilla is often compromised by reduced bone volume. This anatomical condition limits the implant placement of 10 mm in length without sinus augmentation. The use of shorter implants with osteotome technique minimizes the need of more extensive sinus floor elevation, thus reducing the duration and morbidity of the treatment. MATERIALS AND METHODS. A prospective study was conducted of all patients treated between Nov 2007 and Nov 2008 who received endosseous implants that were less than 10 mm in length. Patient age, gender, height bone residual of posterior maxilla, location of implants, number and type of implants and Albrektsson criteria for success were assessed.

RESULTS

A total of 25 implants of 8 mm in length were placed with primary stability in 11 patients. Cumulative survival rates for implants were 100%. CONCLUSION. This simplified treatment modality can make implant rehabilitation of the atrophic posterior maxilla more accessible.

New abutment for a screw-retained, implant-supported crown

The 1-piece, implant-supported abutment and crown, colloquially described as the UCLA abutment, commonly is used to fabricate single, screw-retained crowns. This abutment was designed to allow attachment of the crown directly to the implant and requires a waxing and casting procedure by a laboratory technician. A new prefabricated abutment has been developed that uses a similar approach but does not require the waxing and casting process. The PDQ abutment is made from a metal-ceramic alloy that is custom contoured by grinding to support a porcelain veneer. Porcelain then is fired to the contoured abutment to develop the 1-piece artificial crown. This article describes the use of the PDQ abutment.